姓名：邓锡云

照片：

职称：教授、博士生导师

职务：基础医学博士/硕士学位点负责人；湖南师范大学肿瘤干细胞与转化医学重点实验室主任

联系电话：0731-88912415（Office）

电子邮箱：dengxiyunmed@hunnu.edu.cn

简介

邓锡云，医学博士，湖南师范大学教授、博士生导师，基础医学博士/硕士学位点负责人，肿瘤干细胞与转化医学重点实验室主任。2006年毕业于中南大学获医学博士学位，曾在美国德克萨斯大学医学中心从事博士后研究并担任助理教授。2012年回国后加入九州官方· （中国）官方网站,，入选湖南师范大学“世承人才”计划。担任多个国际及国内期刊编委及审稿专家，为《湖南师范大学学报(医学版)》常务编委。长期从事肿瘤干细胞的基础与转化研究，特别是在三阴性乳腺癌干细胞靶向治疗领域取得了一系列创新性成果。

主持国家自然科学基金面上项目5项、区域创新发展联合基金重点项目子课题1项，以及其他省部级项目多项。以第一或通讯作者在Clinical Cancer Research、International Journal of Biological Sciences、Journal of Hematology & Oncology、Breast Cancer Research等国际知名期刊发表论文。主编三阴性乳腺癌英文专著1部、专刊1期。研究成果获湖南省自然科学奖三等奖。在人才培养方面，已培养博士、硕士研究生多名，多人获得国家奖学金等荣誉；指导青年教师获国家自然科学基金面上项目和青年基金多项。

工作经历

2019.09—至今湖南师范大学基础医学博士/硕士学位点负责人

2018.05—至今湖南师范大学肿瘤干细胞与转化医学重点实验室主任

2016.06—2024.03九州官方· （中国）官方网站,基础医学系主任

2014.12—至今九州官方· （中国）官方网站,病理学与病理生理学教授

2012.12—2014.11九州官方· （中国）官方网站,病理学教研室副研究员

2010.10—2012.11美国德克萨斯大学医学中心外科教研室助理教授

2007.12—2010.09美国德克萨斯大学医学中心博士后助理研究员

2005.12—2007.11中南大学湘雅医学院肿瘤研究所肿瘤分子生物学研究室副研究员

2003.08—2005.11美国俄亥俄州立大学实验动物学系研究助理

2001.12—2003.07美国密歇根州韦恩州立大学医学院泌尿和病理教研室助理研究员

1999.12—2001.11 湖南医科大学肿瘤研究所肿瘤分子生物学研究室副研究员、副主任

1997.12—1999.11 美国国立卫生研究院（NIH）国立癌症研究所（NCI）访问学者

1994.07—1997.11 湖南医科大学肿瘤研究所肿瘤分子生物学研究室助理研究员

主要研究方向

1、三阴性乳腺癌干细胞靶向药物的研发及作用机制

2、肿瘤微环境及代谢重编程

学术兼职

·中国病理生理学会肿瘤专业委员会委员

·湖南省病理生理学会常务理事、肿瘤专业委员会副主任委员

·《湖南师范大学学报(医学版)》常务编委

·《Journal of Cancer》、《Frontiers in Oncology》、《Journal of Cancer》、《肿瘤药学》等杂志编委

获得的人才项目（荣誉）

湖南师范大学“世承人才”（2019年、2024年）

科研项目

1.国家自然科学基金区域创新发展联合基金重点项目(子课题)

项目名称：神经浸润调控三阴性乳腺癌肿瘤微环境和免疫治疗疗效的机制研究和临床转化

批准号：U24A20736 (2025-2028) 经费：80万元

2.国家自然科学基金面上项目(5项)

1)项目名称：核受体PXR在洛伐他汀促进三阴性乳腺癌干细胞对多柔比星敏感性中的作用及机制

批准号：82173374起止日期：2022.01-2025.12 经费：55万元

2)项目名称：洛伐他汀通过核仁应激介导的自噬抑制三阴性乳腺癌干细胞作用的分子机制

批准号：81872167起止日期：2019.01-2022.12 经费：58万元

3)项目名称：洛伐他汀靶向乳腺癌干细胞抑制EMT和转移的作用及机制

批准号：81472496起止日期：2015.01-2018.12 经费：70万元

4)项目名称：EB病毒LMP1调节趋化因子受体CXCR4活性促进鼻咽癌转移的分子机制研究

批准号：30771966起止日期：2008.01-2010.12 经费：32万元

5)项目名称：趋化因子受体EBI1/CCR7在鼻咽癌转移中的作用

批准号：30170877起止日期：2002.01-2003.12经费：16万元

代表性学术论文（中科院二区及以上；标注*为通讯作者，^#为第一作者）

1)Mengzhou Shen^#, Xianjie Jiang^#, Qiu Peng, Linda Oyang, Zongyao Ren, Jiewen Wang, Mingjing Peng, Yujuan Zhou,Xiyun Deng*, Qianjin Liao*. The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications.Journal of Hematology & Oncology2025; 18(1):40 - 58.

2)Chanjuan Zheng, Hui Yao, Lu Lu, Hongqi Li, Lei Zhou, Xueyan He, Xi Xu, Hongzhuo Xia, Siyu Ding, Yiyuan Yang, Xinyu Wang, Muyao Wu, Lian Xue, Sisi Chen, Xiaojun Peng, Zhongyi Cheng, Yian Wang, Guangchun He, Shujun Fu, Evan T. Keller, Suling Liu*, Yi-zhou Jiang*,Xiyun Deng*. Dysregulated Ribosome Biogenesis Is a Targetable Vulnerability in Triple-Negative Breast Cancer: MRPS27 as a Key Mediator of the Stemness-inhibitory Effect of Lovastatin.International Journal of Biological Sciences2024; 20 (6):2130 - 2148.

3)Xinyu Wang, Chanjuan Zheng, Hui Yao, Yuxuan Guo, Yian Wang, Guangchun He, Shujun Fu,Xiyun Deng*. Disulfidptosis: Six Riddles Necessitating Solutions.International Journal of Biological Sciences2024; 20 (3):1042 - 1044.

4)Chanjuan Zheng^#, Xi Xu^#, Muyao Wu^#, Lian Xue, Jianyu Zhu, Hongzhuo Xia, Siyu Ding, Shujun Fu, Xinyu Wang, Yian Wang, Guangchun He, Xia Liu*,Xiyun Deng*.Neutrophils in Triple-Negative Breast Cancer: An Underestimated Player with Increasingly Recognized Importance.Breast Cancer Research2023; 25 (1):88-99.

5)Liujiang Song^#, Xiaojun Tao^#, Li Lin^#, Chao Chen, Hui Yao, Guangchun He, Guangyang Zou, Zhong Cao, Shichao Yan, Lu Lu, Huimei Yi, Di Wu, Siyuan Tan, Wanxin Ouyang, Zhifei Dai*,Xiyun Deng*. Cerasomal Lovastatin Nanohybrids for Efficient Inhibition of Triple-Negative Breast Cancer Stem Cells to Improve Therapeutic Efficacy.ACS Applied Materials & Interfaces2018; 10 (8):7022 - 7030.

6)Xiyun Deng, Guangchun He, Junwen Liu, Feijun Luo, Xiaoning Peng, Shigang Tang, Zhiyong Gao, Qinlu Lin, Jill M Keller, Tao Yang*, Evan T Keller*. Recent Advances in Bone-Targeted Therapies of Metastatic Prostate Cancer.Cancer Treatment Reviews2014; 40 (6):730 - 738.

7)Xiyun Deng*, Guangchun He, Andrea Levine, Ya Cao, Chad Mullins. Adenovirus-mediated Expression of TIMP-1 and TIMP-2 in Bone Inhibits the Growth of Human Prostate Cancer.International Journal of Cancer2008; 122 (1):209 - 218.

8)Xiyun Deng*, Sunita Bhagat, Zhong Dong, Chadwick Mullins, Sreenivasa Rao Chinni, Michael Cher. Tissue inhibitor of metalloproteinase-3 induces apoptosis in prostate cancer cells and confers increased sensitivity to paclitaxel.European Journal of Cancer2006; 42 (18):3267 - 3273.

9)Jinyue Hu^#,Xiyun Deng^#, Xiuwu Bian, Guancheng Li, Yongqing Tong, Yuehui Li, Qingliang Wang, Rong Xin, Xiaojuan He, Guohua Zhou, Pingli Xie, Yanwen Li, Ji Ming Wang, Ya Cao*. The expression of functional chemokine receptor CXCR4 is associated with the metastatic potential of human nasopharyngeal carcinoma.Clinical Cancer Research2005; 11 (13):4658 - 4665.

10)Xiyun Deng, Hirotsugu Ueda, Shao Bo Su, Wanghua Gong, Nancy M. Dunlop, Ji-Liang Gao, Philip M. Murphy, Ji Ming Wang*. A synthetic peptide derived from human immunodeficiency virus type 1 gp120 downregulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the 7-transmembrane G-protein-coupled receptor FPRL1/LXA4R.Blood1999; 94 (4):1165 - 1173.

11)Xiyun Deng*, Chanjuan Zheng, Faqing Tang, Thomas J Rosol, Zhi-Ming Shao*. Editorial: Triple-Negative Breast Cancer: Heterogeneity, Tumor Microenvironment and Targeted Therapy.Frontiers in Oncology2022; 12:1026566.

12)Zhe-Yu Hu^#, Chanjuan Zheng^#, Jianbo Yang^#, Siyu Ding, Can Tian, Ning Xie, Lian Xue, Muyao Wu, Shujun Fu, Zhouzhou Rao, Matthew A Price, James B McCarthy, Quchang Ouyang*, Jizhen Lin*,Xiyun Deng*. Co-expression and Combined Prognostic Value of CSPG4 and PDL1 in TP53-aberrant Triple-Negative Breast Cancer.Frontiers in Oncology2022; 12:804466.

13)Sisi Chen, Ying Li, Muyao Wu, Lian Xue, Jianyu Zhu, Mi Wu, Qiuting Zhang, Guangchun He, Guifei Li, Shujun Fu, Chanjuan Zheng*,Xiyun Deng*. Nucleolar and Coiled-Body Phosphoprotein 1 (NOLC1) Is Associated with Stemness and Represents a Potential Therapeutic Target in Triple-Negative Breast Cancer.Frontiers in Oncology2022; 12:731528.

14)Shichao Yan^#, Da Tang^#, Zhangyong Hong, Jing Wang, Hui Yao, Lu Lu, Huimei Yi, Shujun Fu, Chanjuan Zheng, Guangchun He, Heng Zou, Xuyang Hou, Qing He, Li Xiong*, Qinglong Li*,Xiyun Deng*. CD133 peptide-conjugated pyropheophorbide-a as a novel photosensitizer for targeted photodynamic therapy in colorectal cancer stem cells.Biomaterials Science2021; 9 (6):2020 - 2031.

15)Chanjuan Zheng^#, Shichao Yan^#, Lu Lu^#, Hui Yao, Guangchun He, Sisi Chen, Ying Li, Xiaojun Peng, Zhongyi Cheng, Mi Wu, Qiuting Zhang, Guifei Li, Shujun Fu,Xiyun Deng*. Lovastatin Inhibits EMT and Metastasis of Triple-Negative Breast Cancer Stem Cells Through Dysregulation of Cytoskeleton-Associated Proteins.Frontiers in Oncology2021; 11:656687.

16)Ying Li^#, Zhijun Zhan^#, Xuemin Yin, Shujun Fu*,Xiyun Deng*. Targeted Therapeutic Strategies for Triple-Negative Breast Cancer.Frontiers in Oncology2021; 11:731535.

17)Huimei Yi^#, Ying Li^#, Yuan Tan^#, Shujun Fu*, Faqing Tang*,Xiyun Deng*. Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives.Frontiers in Oncology2021; 11:648139.

18)Di Wu^#, Yao Chen^#, Shun Wen, Yi Wen, Rong Wang, Qiuting Zhang, Ge Qin, Huimei Yi, Mi Wu, Lu Lu, Xiaojun Tao*,Xiyun Deng*. Synergistically enhanced inhibitory effects of pullulan nanoparticle-mediated co-delivery of lovastatin and doxorubicin to triple-negative breast cancer cells.Nanoscale Research Letters2019; 14 (1):314 - 325.

19)Liang Zeng,Xiyun Deng*, Jingmin Zhong, Li Yuan, Xiaojun Tao, Sai Zhang, Yong Zeng, Guangchun He, Pingping Tan, Yongguang Tao*. Prognostic value of biomarkers EpCAM and αB-crystallin associated with lymphatic metastasis in breast cancer by iTRAQ analysis.BMC Cancer2019; 9 (1):831 - 841.

20)Hui Yao, Guangchun He, Chao Chen, Shichao Yan, Lu Lu, Liujiang Song, K Vinod Vijayan, Qinglong Li, Li Xiong, Xiongying Miao,Xiyun Deng*. PAI1: a novel PP1-interacting protein that mediates human plasma's anti-apoptotic effect in endothelial cells.Journal of Cellular and Molecular Medicine2017; 21 (9):2068 - 2076.

21)Xiyun Deng, Yanna Cao, Yan Liu, Fazhi Li, Kamalanathan Sambandam, Srinivasan Rajaraman, Archibald S Perkins, Alan P Fields, Mark R Hellmich, Courtney M Townsend Jr, E Aubrey Thompson, Tien C Ko*. Overexpression of Evi-1 oncoprotein represses TGF-β signaling in colorectal cancer.Molecular Carcinogenesis2013; 52 (4):255 - 264.

专著

Xiyun Deng,Faqing Tang, Thomas J. Rosol. (2020).Triple-Negative Breast Cancer. Singapore: World Scientific Publishing. (ISBN 978-981-3277-75-5)

https://www.worldscientific.com/worldscibooks/10.1142/11199

专刊

Xiyun Deng, Faqing Tang, Thomas J Rosol: Triple-Negative Breast Cancer: Heterogeneity, Tumor Microenvironment and Targeted Therapy.Frontiers in Oncology2021（本人为第一主编）

https://www.frontiersin.org/research-topics/17273

获奖

湖南省自然科学奖三等奖(2022)

获奖名称：洛伐他汀靶向乳腺癌干细胞的作用和机制研究

证书号：20212033-Z3-212-R01